Aravax Ltd, a developer of immunotherapies for food allergy, has appointed two executives experienced in allergy medications to its board. They are Carsten Hellmann, former CEO of ALK-Abello A/S, and Andrew Oxtoby, former chief commercial officer of Aimmune Therapeutics. Mr Hellmann was CEO for almost a decade at ALK-Abello, a leader in allergy diagnosis and allergen immunotherapy. Mr Oxtoby built the commercial organisation for the approval and launch in the US and Europe of Palforzia, the first approved treatment for peanut allergy. The appointments support the Australia-headquartered company’s moves to further develop its lead product, PVX108, for the treatment of peanut allergy. It is currently in Phase 2 trials.
Aravax announced the appointments on 8 April 2026.
Copyright 2026 Evernow Publishing Ltd.